AR080263A1 - Inhibidores ns5a de vhc - Google Patents

Inhibidores ns5a de vhc

Info

Publication number
AR080263A1
AR080263A1 ARP090104676A ARP090104676A AR080263A1 AR 080263 A1 AR080263 A1 AR 080263A1 AR P090104676 A ARP090104676 A AR P090104676A AR P090104676 A ARP090104676 A AR P090104676A AR 080263 A1 AR080263 A1 AR 080263A1
Authority
AR
Argentina
Prior art keywords
heteroaryl
group
independently
heterocycle
aryl
Prior art date
Application number
ARP090104676A
Other languages
English (en)
Original Assignee
Presidio Pharnaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR080263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Presidio Pharnaceuticals Inc filed Critical Presidio Pharnaceuticals Inc
Publication of AR080263A1 publication Critical patent/AR080263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Composiciones farmacéuticas y terapias de combinacion para la inhibicion de la hepatitis C. Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1): donde A se selecciona del grupo formado por: -(CR2)n-C(O)-(CR2)p-, -(CR2)n-O-(CR2)p-, -(CR2)n-N(RN)-(CR2)p-, -(CR2)n-S(O)k-N(RN)-(CR2)p-, -(CR2)n-C(O)-N(RN)-(CR2)p-, -(CR2)n-N(RN)-C(O)-N(RN)-(CR2)p-, -(CR2)n-C(O)-O-(CR2)p-, -(CR2)n-N(RN)-S(O)k-N(RN)-(CR2)p-, y -(CR2)n-N(RN)-C(O)-O-(CR2)p-, y un grupo heteroarilo seleccionado del grupo formado por: (2) donde X1 es CH2, NH, O o S, Y1, Y2 y Z1 son, cada uno, independientemente, CH o N, X2 es NH, O o S, V es -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- o -(CH2)a-O-(CH2)b-, donde a y b son, independientemente 0, 1, 2, o 3 con la condicion de que a y b no sean ambos 0, (3), incluye opcionalmente 1 o 2 nitrogenos como heteroátomos en el residuo fenilo, los carbonos del grupo heteroarilo están, cada uno, independiente y opcionalmente sustituidos con un sustituyente seleccionado del grupo formado por halogeno, -OH, -CN, -NO2, halogeno, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino, los nitrogenos del grupo heteroarilo, si están presentes, están, cada uno, independiente y opcionalmente sustituidos con un sustituyente seleccionado del grupo formado por -OH, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida, a y b son independientemente 1, 2, o 3. c y d son independientemente 1 o 2, n y p son independientemente 0, 1, 2 o 3, k es 0, 1, o 2, cada R se selecciona independientemente del grupo formado por hidrogeno, halogeno, -OH, -CN, -NO2, halogeno, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino. Cada RN se selecciona independientemente del grupo formado por hidrogeno, -OH, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato y sulfonamida, y donde B puede estar ligado a cualquier lado de A' de manera que, siendo el ejemplo de A': (4) W-B-A' puede ser o (5) o (6); B y B' son, cada uno, independientemente un anillo de 4 a 7 miembros que es un arilo, heteroarilo, cicloalquilo o heterociclo donde cada heteroátomo, si está presente, es, independientemente, N, O o S y donde al menos uno de B o B' es aromático; cada Ra se selecciona independientemente del grupo formado por -OH, -CH, -NO2, halogeno, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; y si B o B' no son aromáticos, también puede estar sustituido con uno o más oxo; cada r se selecciona independientemente del grupo formado por 0, 1, 2 y 3; W se selecciona independientemente entre (7) donde: X1 es CH2, NH, O o S, Y1, Y2 y Z1 son, cada uno, independientemente CH o N, X2 es NH, O o S, V es -CH2-CH2-, -CH=CH-, -N=CH-, (CH2)a-N(RN)-(CH2)b- o -(CH2)a-O-(CH2)b-, donde a y b son independientemente 0, 1, 2, o 3 con la condicion de que a y b no sean ambos 0, (3) incluye opcionalmente 1 o 2 nitrogenos como heteroátomos en el residuo fenilo, W está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por OH, -CH, -NO2, halogeno, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino, W y el anillo B' pueden estar conectados mediante cualquiera de: un átomo de carbono o nitrogeno en B', y Cy es un cicloalquilo monociclico o bicíclico de 5 a 10 miembros, heterociclo, grupo arilo o grupo heteroarilo donde hasta tres heteroátomos son, independientemente, N, S u O y que está opcionalmente sustituido con uno o más sustituyentes seleccionados del grupo formado por OH, -CH, -NO2, halogeno, alquilo de C1-12, heteroarilo de C1-12, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, alcoxilo, alcoxicarbonilo, alcanoilo, carbamoilo, sulfonilo sustituido, sulfonato, sulfonamida y amino; cada Rc, Rd, Re y Rf se selecciona, independientemente, del grupo formado por: alquilo de C1-8, heteroalquilo de C1-8, aralquilo y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, donde cada heteroátomo, si está presente, es independientemente N, O o S, cada Rc, Rd, Re y Rf puede estar opcionalmente sustituido por alquilo de C1-8, heteroalquilo de C1-8, aralquilo y un anillo de 4 a 8 miembros que puede ser cicloalquilo, heterociclo, heteroarilo o arilo, y donde cada heteroátomo, si está presentes, es independientemente N, O o S, Rc y Rd están opcionalmente ligados para formar un heterociclo de 4 a 8 miembros que está opcionalmente fusionado con otro heterociclo o anillo heteroarilo de 3 a 5 miembros, y Re y Rf están opcionalmente ligados para formar un heterociclo de 4 a 8 miembros que está opcionalmente fusionado con otro heterociclo o anillo heteroarilo de 3 a 5 miembros; Y e Y' son, cada uno, independientemente, carbono o nitrogeno; y Z y Z' se seleccionan independientemente del grupo formado por hidrogeno, alquilo de C1-8, heteroalquilo de C1-8, cicloalquilo, heterociclo, arilo, heteroarilo, aralquilo, 1-3 aminoácidos, -[U-(CR42)t-NR5-C(R42)t]u-U-(CR42)t-NR7-(CR42)t-R8, -U-(CR42)t-R8, y -[U-(CR42)t-NR5-(CR42)t]u-U-(CR42)t-O-(CR42)t-R8, donde U se selecciona del grupo formado por -C(O)-, -C(S)-, y -S(O)2-, cada R4, R5 y R7 se selecciona independientemente del grupo formado por hidrogeno, alquilo de C1-8, heteroalquilo de C1-8, cicloalquilo, hererociclo, arilo, heteroarilo, aralquilo, R8 se selecciona del grupo formado por hidrogeno, alquilo de C1-8, heteroalquilo de C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo, -C(O)-R81, -C(S)-R81, -C(O)-O-R81, -C(O)-N-, R812, -S(O)2-R81, -S(O) 2-N-R812, donde cada R81 se elige independientemente del grupo formado por hidrogeno, alquilo de C1-8, heteroalquilo de C1-8, cicloalquilo, heterociclo, arilo, heteroarilo y aralquilo, opcionalmente, R7 y R8 juntos forman un anillo de 4-7 miembros, cada t es independientemente 0, 1, 2, 3, o 4, y u es 0, 1 o 2.
ARP090104676A 2008-12-03 2009-12-03 Inhibidores ns5a de vhc AR080263A1 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11972308P 2008-12-03 2008-12-03
US21488109P 2009-04-28 2009-04-28
US17359009P 2009-04-28 2009-04-28
US18295809P 2009-06-01 2009-06-01
US18295209P 2009-06-01 2009-06-01
PCT/US2009/066459 WO2010065674A1 (en) 2008-12-03 2009-12-02 Inhibitors of hcv ns5a

Publications (1)

Publication Number Publication Date
AR080263A1 true AR080263A1 (es) 2012-03-28

Family

ID=42233599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104676A AR080263A1 (es) 2008-12-03 2009-12-03 Inhibidores ns5a de vhc

Country Status (27)

Country Link
US (2) US8921369B2 (es)
EP (2) EP2373172B1 (es)
JP (1) JP5762971B2 (es)
KR (1) KR101784830B1 (es)
CN (2) CN102647909B (es)
AR (1) AR080263A1 (es)
AU (1) AU2009322393B2 (es)
BR (1) BRPI0922366B8 (es)
CA (1) CA2746004C (es)
CL (1) CL2011001333A1 (es)
CO (1) CO6390077A2 (es)
CY (1) CY1114509T1 (es)
DK (1) DK2373172T3 (es)
EA (1) EA024853B1 (es)
ES (1) ES2437156T3 (es)
HK (1) HK1203929A1 (es)
HR (1) HRP20130944T1 (es)
IL (2) IL213277A (es)
MX (1) MX2011005898A (es)
PE (2) PE20150939A1 (es)
PL (1) PL2373172T3 (es)
PT (1) PT2373172E (es)
SG (1) SG171889A1 (es)
SI (1) SI2373172T1 (es)
TW (2) TWI480278B (es)
WO (1) WO2010065674A1 (es)
ZA (1) ZA201104833B (es)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5762971B2 (ja) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
AU2009322400A1 (en) * 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8420686B2 (en) 2009-02-17 2013-04-16 Enanta Pharmaceuticals, Inc. Linked diimidazole antivirals
US8637561B2 (en) 2009-02-17 2014-01-28 Enanta Pharmaceuticals, Inc. Linked diimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CA2753382C (en) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
AU2013204195B2 (en) * 2009-02-27 2016-09-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8426458B2 (en) 2009-02-27 2013-04-23 Enanta Pharmaceuticals, Inc. Hepatitis C Virus inhibitors
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
CN109651342A (zh) 2009-03-27 2019-04-19 默沙东公司 丙型肝炎病毒复制的抑制剂
US8709999B2 (en) 2009-03-27 2014-04-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) * 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG175144A1 (en) 2009-04-15 2011-11-28 Abbott Lab Anti-viral compounds
BRPI1010795B1 (pt) * 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
AU2012203474B2 (en) * 2009-06-11 2014-09-18 Abbvie Ireland Unlimited Company Anti-Viral Compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PE20110679A1 (es) * 2009-06-11 2011-10-20 Abbvie Bahamas Ltd Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011004276A1 (en) * 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
CN102656160A (zh) 2009-07-16 2012-09-05 顶点制药公司 用于治疗或预防黄病毒感染的苯并咪唑类似物
CN102480971B (zh) 2009-09-04 2014-11-26 杨森制药公司 化合物
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110152246A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
RU2554087C2 (ru) 2009-12-18 2015-06-27 Айденикс Фармасьютикалз, Инк. 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с
JP2013515068A (ja) * 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20130244A1 (es) 2010-01-25 2013-03-10 Enanta Pharm Inc Inhibidores del virus de la hepatitis c
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2679918T3 (es) 2010-02-18 2018-08-31 Vtv Therapeutics Llc Derivados de imidazol condensados sustituidos, composiciones farmacéuticas y métodos de uso de los mismos
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012022311A2 (pt) * 2010-03-04 2016-08-23 Enanta Pharm Inc agentes farmacêuticos de combinação como inibidores da replicação de hcv.
CN102918049A (zh) 2010-03-09 2013-02-06 默沙东公司 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法
MX2012010918A (es) 2010-03-24 2013-01-18 Vertex Pharma Analogos para el tratamiento o prevencion de infecciones por flavivirus.
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
EP2575866A4 (en) * 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8486938B2 (en) 2010-06-24 2013-07-16 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines for antiviral treatment
AU2011276526A1 (en) 2010-06-28 2013-01-10 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
BR112013002122A2 (pt) * 2010-07-26 2016-09-20 Janssen R&D Ireland derivados hetero-bicíclicos como inibidores de hcv
AU2011286276A1 (en) 2010-07-26 2013-01-24 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20120195857A1 (en) * 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
CN103459399A (zh) * 2010-09-29 2013-12-18 默沙东公司 用于治疗丙型肝炎病毒感染的四环吲哚衍生物
MX2013003631A (es) * 2010-09-29 2013-10-01 Merck Sharp & Dohme Derivados de indol tetraciclicos y sus métodos para el tratamiento de enfermedades virales.
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
AU2014203655B2 (en) * 2010-10-13 2016-07-07 Abbvie Ireland Unlimited Company Anti-viral compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN103687489A (zh) 2011-05-18 2014-03-26 埃南塔制药公司 制备5-氮杂螺[2.4]庚烷-6-甲酸及其衍生物的方法
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
CA2841095A1 (en) * 2011-07-09 2013-01-17 Sunshine Lake Pharma Co., Ltd. Spiro compounds as hepatitis c virus inhibitors
CN103781786A (zh) 2011-07-15 2014-05-07 盐野义制药株式会社 具有ampk活化作用的氮杂苯并咪唑衍生物
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
EP2736893A1 (en) 2011-07-26 2014-06-04 Vertex Pharmaceuticals Incorporated Thiophene compounds
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
MX2014006745A (es) * 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
EP2794611B1 (en) 2011-12-22 2017-10-11 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
JP6170944B2 (ja) 2011-12-28 2017-07-26 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｈｃｖ阻害剤としてのヘテロ−二環式誘導体
BR112014016007A8 (pt) * 2011-12-28 2017-07-04 Janssen R&D Ireland derivados de quinazolinona como inibidores de vhc
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013123092A1 (en) * 2012-02-13 2013-08-22 Presidio Pharmaceuticals, Inc. Solid forms comprising inhibitors of hcv ns5a, compositions thereof, and uses therewith
CA2866556C (en) 2012-03-09 2020-01-07 Fibrogen, Inc. 4 -hydroxy-isoquinoline compounds as hif hydroxylase inhibitors
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
EA027855B1 (ru) 2012-04-17 2017-09-29 Гайлид Сайэнсиз, Инк. Соединения и способы для противовирусной терапии
JP6006008B2 (ja) * 2012-06-14 2016-10-12 ユー・ディー・シー アイルランド リミテッド 化合物、有機電界発光素子並びに該有機電界発光素子を用いた発光装置、表示装置及び照明装置
TWI610916B (zh) * 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN102796084A (zh) * 2012-09-10 2012-11-28 合肥科尚医药科技有限公司 一种活性物质及其在治疗丙型肝炎中的应用及制备方法
WO2014055069A1 (en) * 2012-10-02 2014-04-10 Presidio Pharmaceuticals, Inc. Solid forms comprising an inhibitor of hcv ns5a, compositions thereof, and uses therewith
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
BR112015013121A2 (pt) * 2012-12-06 2017-07-11 Baruch S Blumberg Inst derivados funcionalizados de benzamida como agentes antivirais contra infecção por hbv
WO2014110687A1 (en) 2013-01-16 2014-07-24 Merck Sharp & Dohme Corp. Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
JP2016527232A (ja) 2013-07-17 2016-09-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2015089810A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
CN104860935A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 作为丙肝病毒抑制剂的噻吩或其变体衍生物及其制药用途
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN107663196A (zh) * 2016-07-27 2018-02-06 广东东阳光药业有限公司 制备化合物的方法
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
CN113167802B (zh) 2018-12-04 2025-02-07 百时美施贵宝公司 通过多同位素体反应监测使用样品内校准曲线的分析方法
JP7269584B2 (ja) * 2019-04-08 2023-05-09 国立大学法人千葉大学 キノリン化合物の製造方法
CN110498759A (zh) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 异吲哚啉酮类化合物的合成方法
WO2022078407A1 (en) * 2020-10-13 2022-04-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117321059A (zh) 2021-05-21 2023-12-29 吉利德科学公司 用于治疗寨卡病毒感染的四环化合物
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物
AU2022370483A1 (en) * 2021-10-20 2024-05-02 Assembly Biosciences, Inc. Novel crystalline forms
CN114262263B (zh) * 2021-12-28 2024-04-19 河北美星化工有限公司 一种4-碘苯酚的制备方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2526230A1 (de) * 1975-06-12 1976-12-16 Hoechst Ag Neue benzoxazol-derivate, verfahren zu ihrer herstellung und ihre anwendung als optische aufheller
CA2034309C (en) * 1990-01-22 1997-04-01 Takashi Iwaki Mesomorphic compound, liquid crystal composition containing same, liquid crystal device using same and display apparatus
ATE203234T1 (de) 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
PL192628B1 (pl) 1996-04-23 2006-11-30 Vertex Pharma Pochodne mocznika, kompozycje farmaceutyczne i zastosowanie związku i kompozycji
DE69709671T2 (de) 1996-10-18 2002-08-22 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
EA200000768A1 (ru) 1998-01-27 2001-06-25 Эвентис Фармасьютикалз Продактс Инк. ЗАМЕЩЕННЫЕ ОКСОАЗАГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ФАКТОРА Ха
ES2244204T3 (es) 1998-07-27 2005-12-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Derivados de dicetoacidos como inhibidores de polimerasas.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002523371A (ja) 1998-08-21 2002-07-30 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患を治療または予防するための化合物、組成物および方法
EP1109580A4 (en) 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
EP1115286A4 (en) 1998-09-25 2003-07-23 Viropharma Inc METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM
AU769383B2 (en) 1999-03-19 2004-01-22 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
US20040034041A1 (en) 2000-05-10 2004-02-19 Dashyant Dhanak Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
PT1401825E (pt) 2001-06-11 2009-10-23 Virochem Pharma Inc Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus
JP2005500287A (ja) 2001-06-11 2005-01-06 シャイアー バイオケム インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
EP1440070A1 (en) 2001-11-02 2004-07-28 Glaxo Group Limited 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
IL161881A0 (en) 2001-11-08 2005-11-20 Upjohn Co N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
US7189724B2 (en) * 2003-04-15 2007-03-13 Valeant Research And Development Quinoxaline derivatives having antiviral activity
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050131042A1 (en) 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
RS51243B (sr) 2004-01-30 2010-12-31 Medivir Ab. Inhibitori ns-3 serina hcv proteaze
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
MX2007008587A (es) * 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
US7473784B2 (en) * 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2008021851A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2633318T3 (es) 2006-10-23 2017-09-20 Cephalon, Inc. Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5762971B2 (ja) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
AU2009322400A1 (en) * 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2010091413A1 (en) * 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) * 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
CA2753382C (en) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
BRPI1010795B1 (pt) 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
WO2010148006A1 (en) * 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US9156818B2 (en) * 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110152246A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds

Also Published As

Publication number Publication date
CN102647909A (zh) 2012-08-22
IL213277A0 (en) 2011-07-31
JP5762971B2 (ja) 2015-08-12
AU2009322393A1 (en) 2011-07-07
DK2373172T3 (da) 2013-10-21
TW201529569A (zh) 2015-08-01
EP2373172B1 (en) 2013-07-17
CY1114509T1 (el) 2016-10-05
KR101784830B1 (ko) 2017-10-16
CO6390077A2 (es) 2012-02-29
US20130096101A1 (en) 2013-04-18
EA024853B1 (ru) 2016-10-31
US20120122864A1 (en) 2012-05-17
TW201033197A (en) 2010-09-16
WO2010065674A1 (en) 2010-06-10
PT2373172E (pt) 2013-10-21
US8618151B2 (en) 2013-12-31
SG171889A1 (en) 2011-07-28
EP2682393A1 (en) 2014-01-08
CL2011001333A1 (es) 2011-10-28
BRPI0922366B8 (pt) 2021-05-25
WO2010065674A9 (en) 2012-05-31
PE20120124A1 (es) 2012-03-17
CN104163816A (zh) 2014-11-26
HRP20130944T1 (hr) 2013-11-22
PL2373172T3 (pl) 2013-12-31
EP2373172A1 (en) 2011-10-12
PE20150939A1 (es) 2015-07-19
ES2437156T3 (es) 2014-01-09
BRPI0922366B1 (pt) 2020-12-29
TWI573796B (zh) 2017-03-11
CA2746004A1 (en) 2010-06-10
JP2012510524A (ja) 2012-05-10
KR20110098780A (ko) 2011-09-01
ZA201104833B (en) 2012-03-28
TWI480278B (zh) 2015-04-11
EA201190013A1 (ru) 2012-02-28
CA2746004C (en) 2017-06-06
EP2373172A4 (en) 2012-08-01
CN102647909B (zh) 2014-06-25
US8921369B2 (en) 2014-12-30
SI2373172T1 (sl) 2013-12-31
IL233818A0 (en) 2014-09-30
AU2009322393B2 (en) 2017-02-02
HK1203929A1 (en) 2015-11-06
IL213277A (en) 2014-08-31
MX2011005898A (es) 2011-09-27

Similar Documents

Publication Publication Date Title
AR080263A1 (es) Inhibidores ns5a de vhc
AR084388A1 (es) Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen
AR080264A1 (es) Inhibidores ns5a de vhc
AR081831A1 (es) Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc)
AR076164A1 (es) Inhibidores de anillos fusionados de hepatitis c
AR084720A1 (es) Inhibidores de anillos fusionados triciclicos de hepatitis c
AR068794A1 (es) Compuestos antivirales
AR061840A1 (es) Compuestos fosfinatos antivirales
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
AR061220A1 (es) Derivados de tiazol
CO6160296A2 (es) Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol
AR058700A1 (es) Compuestos heterociclicos como bloqueadores del canal de sodio epitelial
AR060405A1 (es) Compuestos organicos y sus usos en tratamientos de infeccion por el virus de hepatitis c
AR054814A1 (es) Derivados de piridazina
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR061642A1 (es) Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas
AR095339A1 (es) Compuestos moduladores alostericos de la hemoglobina
AR063601A1 (es) Arilamidas sustituidas por tiazol u oxazol
AR076098A1 (es) Derivados de benzofurano
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
CO5640041A2 (es) Un inhibidor de pde4 y un agente anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias
ECSP12012212A (es) Derivados de ariletinilo
AR077240A1 (es) Sulfonamidas heterociclicas, composiciones farmaceuticas de la mismas y su uso en trastornos neurologicos.
AR075718A1 (es) Compuestos heterociclicos antivirales
CO5550501A2 (es) Derivados nucleosidos con accion sobre el virus de la hepatitis c, su procedimiento de sintesis y composiciones que los contienen

Legal Events

Date Code Title Description
FG Grant, registration